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Abstract
Background: Sudan is a large country with a diverse population and history of civil conflict. Poverty levels are high
with a gross national income per capita of less than two thousand dollars. The country has a high burden of
tuberculosis (TB) with an estimated 50,000 incident cases during 2009, when the estimated prevalence was 209
cases per 100,000 of the population. Few studies have been undertaken on TB in Sudan and the prevalence of
drug resistant disease is not known.
Methods: In this study Mycobacterium tuberculosis isolates from 235 patients attending three treatment centers in
Sudan were screened for susceptibility to isoniazid, rifampicin, ethambutol and streptomycin by the proportion
method on Lowenstein Jensen media. 232 isolates were also genotyped by spoligotyping. Demographic details of
patients were recorded using a structured questionnaire. Statistical analyses were conducted to examine the
associations between drug resistance with risk ratios computed for a set of risk factors (gender, age, case status -
new or relapse, geographic origin of the patient, spoligotype, number of people per room, marital status and type
of housing).
Results: Multi drug-resistant tuberculosis (MDR-TB), being resistance to at least rifampicin and isoniazid, was found
in 5% (95% CI: 2,8) of new cases and 24% (95% CI: 14,34) of previously treated patients. Drug resistance was
associated with previous treatment with risk ratios of 3.51 (95% CI: 2.69-4.60; p < 0.001) for resistance to any drug
and 5.23 (95% CI: 2.30-11.90; p < 0.001) for MDR-TB. Resistance was also associated with the geographic region of
origin of the patient, being most frequently observed in patients from the Northern region and least in the Eastern
region with risk ratios of 7.43 (95%CI:3.42,16.18; p: < 0.001) and 14.09 (95%CI:1.80,110.53; p:0.026) for resistance to
any drug and MDR-TB. The major genotype observed was of the Central Asia spoligotype family (CAS1_Delhi),
representing 49% of the 232 isolates examined.
Conclusions: We conclude that emergence of drug resistant tuberculosis has the potential to be a serious public
health problem in Sudan and that strengthened tuberculosis control and improved monitoring of therapy is
needed. Further surveillance is required to fully ascertain the extent of the problem.
Background
The Republic of Sudan is the largest country on the
African continent covering 2.5 million km2 with a cur-
rent estimated population of approximately 45 million,
42% of whom are believed to be under the age of 15
years [1]. The population is culturally and ethnically
diverse with several hundred tribal groupings speaking
over 130 languages [2]. The country contains 26 states
divided between five geographic regions Eastern, Wes-
tern, Southern, Northern and Central Sudan which
includes the Capital Khartoum. However, following a
recent referendum the region of South Sudan became
an independent state in July 2011 [3]. During 2010 an
estimated 40% of the people lived in an urbanized
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environment [1]. It is a poor country and gross national
income per capita was less than two thousand interna-
tional dollars during 2009 with a life expectancy at birth
of 58 years [4]. The country has been severely affected
by war, famine and flood in recent decades and has a
large population of internally displaced persons [5]. It
has high burden of tuberculosis (TB) with a prevalence
of 209 cases per 100,000 of the population and 50,000
incident cases during 2009 [6]. The estimated adult HIV
prevalence of 1.5% remains lower than that of its Afri-
can neighbors to the south and a report from 2002 sug-
gested 4% of tuberculosis patients were co-infected with
HIV [5]. Tuberculosis care and treatment is provided by
the National Tuberculosis Control Program under the
auspices of the Ministry of Health and by a number of
non-governmental organizations (NGOs) who provide
care to displaced persons, including those living in refu-
gee camps [5]. Treatment is also provided by the private
sector [7]. At the time of this study the Sudan National
TB Program treatment policy was for an intensive phase
of rifampicin, isoniazid, pyrazinamide and streptomycin
daily under direct supervision for two to three months
until the patient became smear negative followed by
eight months of isoniazid and ethambutol [7]. Thioace-
tazone was previously used in the place of ethambutol
[8,9]. Patients unable to attend on a daily basis were put
on a 12-month regimen excluding rifampicin. Smear-
negative pulmonary patients and non severe extra-pul-
monary cases were given isoniazid and ethambutol daily
for twelve months, supplemented by daily streptomycin
injections during the initial phase [5]. While some
NGOs refer patients to the national program others pro-
vide treatment using their own regimens. TB treatment
in the private sector is not regulated [7].
The emergence and spread of strains of tuberculosis
that are resistant to the drugs used in standard first line
treatment poses a serious threat to attempts to control
the disease [10]. Drug resistance in M. tuberculosis
arises through the selection of spontaneous mutations
by inadequate therapy. Resistance to multiple drugs
arises through sequential selection of mutations. Resis-
tance to both the key drugs rifampicin and isoniazid is
termed multi drug-resistant tuberculosis (MDR-TB).
Patients with MDR-TB frequently fail to be cured by
standard drug treatment and may remain infectious and
a potential source of onward transmission. Treatment
for MDR-TB requires alternative chemotherapy for at
least 18 months using more expensive drugs [11]of
heightened toxicity [12,13]. In Sudan treatment is pro-
vided at the Abu-Anga Teaching Hospital [14], where
the drugs available are ciprofloxacin, ofloxacin, cycloser-
ine, ethionamide and amikacin [7]. From 2005 to 2008
small numbers of patients were treated for MDR-TB
[14] but in 2009 ninety four patients commenced
second line treatment, thirty five were new patients and
fifty nine were retreatment cases [6]. The prevalence of
drug resistant TB in Sudan is not known. A previous
study undertaken in central Sudan during 1965 reported
high levels of resistance to the anti-tuberculosis drugs
available at that time [15]. Cure rates have improved
considerably since the establishment of the National
Tuberculosis Control Program and introduction of short
course chemotherapy, but no surveys of drug suscept-
ibility have been reported [5,16]. Examination of isolates
collected 10 years ago by molecular methods found evi-
dence of MDR-TB in 2/39 retreatment cases [17]. The
study also reported the dominance of a single Mycobac-
terium tuberculosis genotype where over half of the
strains examined (29/49) shared the same spoligotype
pattern.
The purpose of the current study was to investigate
the susceptibly to anti-tuberculosis drugs and genotype
of M. tuberculosis strains from patients attending three
treatment centers in Sudan. Treatment history and
demographic characteristics such as the geographic ori-
gin of the patient were recorded and statistical analysis
undertaken to assess genotypic and demographic factors
associated with the emergence of drug resistant disease.
Methods
Scientific and ethical approval for the study was
obtained from Al Neelain Ethical Review Board. Conse-
cutive smear positive pulmonary tuberculosis patients
attending out-patient chest clinics in three cities were
invited to join the study. The recruitment centers were
the Abu Anga Hospital (Omdurman, Central Sudan;
estimated population 1.2 million), Al Shaab Teaching
Hospital (Khartoum, Central Sudan; estimated popula-
tion 1.9 million) and Port Sudan Hospital (Port Sudan,
Eastern Sudan; estimated population 0.5 million) [18].
Study participants were enrolled three days per week,
selected at random during May to December 2005. Spu-
tum samples were requested and demographic data
relating to age, gender, marital status, geographic origin
of patient, tribe, occupation, housing (construction and
numbers of persons) and previous history of tuberculo-
sis was collected via a structured questionnaire. Where
available HIV status was recorded but testing was not
undertaken as part of this study. All participants gave
their informed consent prior to submitting sputum spe-
cimens and answering the questionnaire.
The sputum specimens were decontaminated using 2%
sodium hydroxide and concentrated by centrifugation
prior to investigation by Ziehl-Neelsen smear micro-
scopy [19]. For culture, sedimented samples were inocu-
lated on Lowenstein Jensen (LJ) media containing
glycerol. Following isolation and culture the M. tubercu-
losis strains obtained were screened for resistance to
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isoniazid, rifampicin, ethambutol and streptomycin and
subjected to spoligotyping. For each patient, only the
first available isolate was included in this study. Drug
susceptibility testing was performed at the Sudanese
National Reference Laboratory (Khartoum) for isoniazid,
rifampicin, streptomycin and ethambutol by the propor-
tion method on LJ [20]. Although the laboratory takes
part in a program of external quality control the sam-
ples in this study were not sent to another laboratory
for confirmatory testing.
Spoligotyping was performed on isolated cultures
according to the Kamerbeek method [21] using a com-
mercial kit to test for 43 individual spacers (Isogen, IJs-
selstein, The Netherlands). All DNA extracts were
tested at two dilutions (1:10, 1:100) and the spoligopat-
terns obtained analysed using BioNumerics (Applied
Maths, St-Martens-Latem, Belgium). Results obtained
were compared with the international SITVIT database
(Institut Pasteur, Guadeloupe). A subset of the isolates
was subjected to secondary typing by MIRU/VNTR
(mycobacterial-interspersed repetitive-unit variable num-
ber-tandem-repeats) [22] where variable numbers of
repeats within the genome are identified following
amplification by PCR. Twenty four loci MIRU/VNTR
analysis [23] was performed by a commercial company,
Genoscreen (Lille, France) using a high throughput
DNA Analyzer (3730XL Applied Biosystems). Samples
selected for secondary typing were those found resistant
to rifampicin that shared a common spoligotype.
Statistical analyses were conducted in STATA version
11. Two binary outcome variables were created: 1) resis-
tance to at least one of the TB drugs (isoniazid, rifampi-
cin, streptomycin or ethambutol) and 2) MDR status (an
individual is MDR if resistant to both isoniazid and
rifampicin). Associations between these outcome vari-
ables and a set of risk factors (gender, age, case status -
new or relapse, geographic origin of the patient, spoligo-
type, number of people per room, marital status and
type of housing) were examined. To this end, risk ratios
and their associated Wald-type confidence intervals
were computed, and for hypothesis testing the chi-
square test was used. Exact binomial 95% confidence
intervals were calculated for prevalence estimates.
Results
Full drug resistance data was obtained for strains from
235 patients, 232 of which were genotyped. The geogra-
phical origin of the 235 patients was unevenly spread
with the Western, Eastern, Southern, Northern and
Central regions providing 110 (47%), 54 (23%), 26 (11%),
23 (10%) and 22 (9%) patients respectively. The geo-
graphic spread of patients attending the recruitment
centers is presented in Figure 1. Forty eight tribal
groups were represented. Whereas the mix of patents
attending Abu Anga and Al Shaab Hospitals was similar,
the majority (83%) attending Port Sudan Hospital
belonged to three pastoralist tribes not seen at the other
two centers. The median age of participants was 35
years and the interquartile range was 26-45 years. One
hundred and seventy five (74%) of patients were male.
Reported occupations included unskilled worker or
laborer 31% (n = 72), housework 21% (n = 50), business
11% (n = 26), student 10% (n = 24), unemployed 8% (n
= 19), farmer 7% (n = 17), driver 5% (n = 11) or soldier
2% (n = 4). A majority of women (71%) cited their occu-
pation as being within the home. Forty percent of males
were unskilled workers or laborers and 9% were unem-
ployed. Seventy percent (164) of the patients whose iso-
lates were tested were classed as new patients having
received less than one month of anti-tuberculosis che-
motherapy. Of the remainder 51 (22%) reported having
previously completed a course of TB therapy and were
classed as relapsed cases, 15 (6%) had experienced inter-
rupted treatment and 5 (2%) were treatment failures.
HIV tests results were available for 27 (12%) of patients,
of whom 9 (33%) were HIV positive.
Genotyping results
DNA from 232 M. tuberculosis isolates were available
for genotyping by spoligotyping. Results were compared
with the SITVIT Database (Institut Pasteur, Guade-
loupe). 160 (69%) of isolates had patterns that matched
those in the database. Cluster analysis revealed that a
single spoligotype pattern of the CAS1_Delhi family
(SIT25) was shared by 82 individuals (35%) and that an
additional 32 (14%) patients were infected with strains
of the same lineage but with differing SIT numbers. The
SIT25 pattern is identical to that reported previously as
a being highly clustered in isolates from Khartoum [17].
Of the spoligotype patterns not found in the interna-
tional database a further 12 were identified as having
identical patterns to SIT25 but lacking a single spacer
Figure 1 Distribution of geographic origin of patients by
recruitment centre.
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and for the purposes of further analysis were classified
as belonging the to CAS1_Delhi lineage. The distribu-
tion of spoligotype lineages in the geographic regions of
origin of the patient is presented in Table 1. The preva-
lence of CAS1_Delhi was highest in the Western region
where it was observed in 67% of the cases examined.
A subset of 17 isolates found resistant to rifampicin
and identified as either SIT25 (CAS1_Delhi) and 3 iso-
lates SIT1 (Beijing/W) were subjected to secondary typ-
ing by 24 loci MIRU. The results, as previously reported
elsewhere [24], demonstrated that the rifampicin resis-
tant spoligotype families were not comprised of identical
strains. The 17 isolates with identical SIT25 spoligotype
patterns were subdivided into 11 MIRU types (one clus-
ter of 5, two clusters of 2 and 8 individual MIRU types).
Similarly, the 3 SIT1 isolates were found by MIRU-
VNTR to be a cluster of 2 and a single strain.
Drug susceptibility
127 patients (54%, 95% CI: 47,61) were found to have
tuberculosis that was fully susceptible to isoniazid,
rifampicin, ethambutol and streptomycin. The remaining
108 patients (46%, 95% CI: 39,53) had resistance to at
least one of the four drugs tested while 26 (11%, 95%
CI: 7,16) were classed as MDR-TB, being resistant to at
least isoniazid and rifampicin. The distribution of drug
resistant cases with regard to treatment status is pre-
sented in Table 2. In new cases resistance to at least
one drug was observed in 43 patients (26%, 95% CI:
19,33) with 8 (5%, 95% CI: 2,8) having MDR-TB. In the
71 previously treated patients resistance to at least one
drug was observed in 65 cases (92%, 95%CI: 83,101) and
17 patients (24%, 95% CI: 14,34) had MDR-TB.
When compared to new cases previously treated
patients had significantly increased risk of drug resistant
disease, with a risk ratio of 3.51 (95% CI: 2.69-4.60) for
resistance to any drug and 5.23 (95% CI: 2.30-11.90) for
MDR-TB. Analysis of demographic characteristics of the
population with respect to drug resistance is presented
in Table 3 and for MDR-TB in Table 4. The prevalence
of drug resistance was found to vary by the geographic
origin of the patient, being most prevalent in patients
originating from the Northern region and least prevalent
among those from the East. MDR-TB was found in
patients belonging to 14 of the 48 tribes represented.
The Ja’alya from the Northern region had the highest
number of cases (5/13; 39%) followed by the Jawama
from the West (4/15; 27%). Other tribes in which MDR-
TB was detected included the Dinka (2/16), Hasania (3/
13), Manaseir (1/2) Masalit (1/6), Mesaria (2/10), Mima
(1/1), Nawir (1/4), Nouba (1/15), Rashaida (1/4), Shai-
gyiah (2/15), Shamblia (1/3) and Tama (1/5).
Fifty three patients (23%) were found resistant to
rifampicin of which 26 were also resistant to isoniazid
and were classed as having MDR-TB. Thus the predic-
tive value of rifampicin resistance for MDR-TB (i.e. the
proportion of rifampicin resistant patients who had
MDR-TB) was 49%. The predictive value varied by
region, being 100%, 50%, 50%, 75% and 36% in the Cen-
tral, South, East, North and Western regions
respectively.
Discussion
Sudan is a poor country whose healthcare delivery sys-
tem has been placed under considerable strain in the
past two decades through civil unrest, natural disasters
and other economic factors. We present the first study
to ascertain levels of drug resistant tuberculosis since
the adoption of multi drug short course therapy and
establishment of a DOTS program in 1992 [16]. The
high levels of MDR observed in re-treatment patients
(24%) and variation in the prevalence of resistance
across geographic regions is a cause for concern and
suggests that sub optimal treatment has been adminis-
tered. Evidence of inadequate treatment is provided by a
study of 19 patients attending Abu Anga Hospital dur-
ing 2008 who had failed treatment with first line drugs,
where over half (10) reported interrupted treatment
[14]. Similarly, of 24 patients taking second line treat-
ment for MDR-TB five had interrupted treatment once,
and a further thirteen had interrupted treatment on
more than one occasion. Reasons given for the inter-
rupted treatment were lack of money, lack of drugs and
feeling well. When compared to other reports from the
region the prevalence of MDR in re-treatment patients
is approximately double the estimate for Ethiopia to the
East (12%) [25] and Kampala to the South (13%) [26]
Table 1 Regional distribution of spoligotype lineage by
origin of the patient
Lineage Number (%) of isolates by region.
Central East North South West All
CAS1_Delhi* 10
(45.5)
24
(45.3)
9 (40.9) 10
(38.5)
73 (67) 126
(53.9)
T1 1 (4.5) 8 (15.1) 2 (9.1) 1 (3.9) 4 (3.7) 16 (6.9)
Beijing/W 1 (4.5) 1 (1.9) 1 (4.5) 0 4 (3.7) 7 (3.0)
H3 1 (4.5) 1 (1.9) 0 1 (3.9) 4 (3.7) 7 (3.0)
CAS 1 (4.5) 1 (1.9) 0 0 2 (1.8) 4 (1.7)
LAM7_TUR 1 (4.5) 2 (3.8) 0 0 0 3 (1.3)
U 0 3 (5.7) 0 0 0 3 (1.3)
T2 0 0 0 0 3 (2.8) 3 (1.3)
S 0 1 (1.9) 0 0 0 1 (0.4)
LAM9 0 1 (1.9) 0 0 1 (0.9) 2 (0.9)
No SIT 7 (31.8) 11
(20.8)
10
(45.5)
14
(53.9)
18
(16.51)
60 (26.3)
*Includes 114 CAS1_Delhi isolates matching SIT patterns 24, 25, 141, 232, 247,
309, 381, 1198, 1203 or 1787 and an additional 12 strains having spoligotype
patterns one spacer different to SIT25.
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but is less that the 38% reported from Egypt, Sudan’s
Northern neighbour [25]. It should be noted that North-
ern Sudan, the region with the highest prevalence of
MDR has been badly affected by both war and drought
and considerable displacement of peoples has occurred.
Egypt is currently host to a large Sudanese refugee and
migrant population with consequent cross border move-
ment. In the population studied those at increased risk
of drug resistance included individuals of male gender
and those living in a brick dwelling or sleeping in a
room shared by more than six persons. Although not
statistically significant these findings suggest that life
style may influence the outcome of treatment and emer-
gence of drug resistant disease.
Whilst the data from this study clearly indicates a pro-
blem with the treatment of tuberculosis in Sudan it does
not provide a full picture of the situation. Three TB
treatment centres were sampled. A fourth centre El
Obeid Hospital in a more southern location was
sampled but susceptibility tests were not completed.
Sampling may have been affected by the location of the
treatment centers as some rural populations may have
reduced access to such urban facilities [8]. The ratio of
males to female participating in the study (2.8) is higher
than that reported nationally (1.7) [6] and may reflect
inequalities of access to the recruitment sites. Further
surveillance is needed to quantify the prevalence of
resistance in Sudan and identify those areas of the coun-
try in need of strengthened TB treatment supervision. In
addition, external quality assurance should be imple-
mented for studies of susceptibility to anti-tuberculosis
drugs. Testing for resistance to second line drugs was
not undertaken during this study and the prevalence of
XDR-TB in Sudan is not known.
Resistance to rifampicin occurs less frequently than
resistance to isoniazid and in many settings may be
taken as an indicator for the presence of MDR-TB [27].
The high level of rifampicin resistance in the absence of
resistance to isoniazid observed in this study (11.5%)
points to inappropriate therapy, where the drugs have
been taken separately rather than in combination. A
review of the management and supply of TB drugs in
Sudan conducted in 2008 noted that appropriate treat-
ment guidelines were often absent from treatment cen-
tres and that control of TB drugs in the private sector
was lacking [7]. They also found that supply problems
resulted in low stocks of combination therapy (isoniazid
plus rifampicin) in some centers and that some stocks
of drugs were past their expiry date. The use of rifampi-
cin to treat other conditions such as brucellosis may
also be a contributory factor [28]. The problem was
most acute in patients originating from the West of
Sudan which includes the regions of Kordofan and
Dafur which have experienced civil unrest in recent
years. It is important that expanded studies are underta-
ken to ascertain the prevalence of monoresistance to
rifampicin in Sudan in accordance with WHO guidelines
[19]. A low predictive value of resistance to rifampicin
for MDR-TB in Sudan would reduce the ability to
Table 2 Susceptibility to anti-tuberculosis drugs by treatment category (Number and %)
Treatment category. Pan susceptible Resistant MDR-TB
Isoniazid Rifampicin Streptomycin Ethambutol I + R
New (N = 164) 121 (73.8) 17 (10.4) 22 (13.4) 24 (14.6) 9 (5.5) 8 (4.9)
Relapse (N = 51) 4 (7.8) 21 (41.2) 20 (39.2) 37 (72.6) 32 (62.8) 13 (25.5)
Interrupted N = 15 2 (13.3) 4 (26.7) 9 (60) 12 (80) 7 (46.7) 4 (26.7)
Failed N = 5 0 1 (20) 2 (40) 3 (60) 5 (100) 0
Table 3 Prevalence of resistance within demographic
subgroups
Variable %
RES
95% CI RR 95% CI P-
value
SEX Male 45.7 38.2,53.4 1
Female 46.7 33.7,60.0 1.02 0.74,1.40 0.898
AGE < = 30 39.5 29.2,50.7 1
31-44 54.8 43.5,65.7 1.39 1.00,1.92
> = 45 43.1 30.8,56.0 1.09 0.74,1.60 0.118
CASE New 26.2 19.7,33.6 1
Relapse 92.2 81.1,97.8 3.51 2.69,4.60
Failure/
Interrupted
90.0 68.3,98.8 3.43 2.55,4.61 < 0.001
ORIGIN East 11.1 4.2,22.6 1
West 53.6 43.9,63.2 4.83 2.23,10.47
North 82.6 61.2,95.0 7.43 3.42,16.18
South 57.7 36.9,76.6 5.19 2.28,11.83
Central 40.9 20.7,63.6 3.68 1.49,9.11 < 0.001
SPOLIGOTYPE CAS1-DEL 49.1 39.6,58.7 1
Other 32.2 20.6,45.6 0.66 0.43,0.99
Unknown 53.2 40.1,66.0 1.08 0.80,1.46 0.043
MARITALSTATUS Married 45.8 36.6,55.2 1
Not
married
46.2 36.9,55.6 1.01 0.76,1.33 0.952
TYPEOFHOUSE Brick 63.9 46.2,79.2 1
Mud 45.6 37.5,54.0 0.71 0.53,0.97
Shelter 36.2 22.7,51.5 0.57 0.36,0.89 0.040
PERSON/ROOM < 6 44.4 34.9,54.3 1
6+ 48.4 39.3,57.5 1.09 0.82,1.44 0.548
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predict MDR-TB when using the new generation of
molecular tests such as the Xpert MTB/RIF (Cepheid,
California, USA) [29] which rely on detection of muta-
tions in a sub unit of the RNA polymerase gene. Data
from neighbouring countries is limited but in 2002 the
predictive value of rifampicin resistance for MDR-TB in
Egypt at 72.4% was also lower than international norms
[30]. That 73% of re-treatment cases and 15% of new
patients were found to have strains resistant to strepto-
mycin suggests that the efficacy of this drug is limited
in this setting. It is an injectable drug that necessitates
regular attendance at a health clinic and the high levels
of resistance observed suggest its role in the treatment
of TB in Sudan should be reappraised.
The predominance of the CAS1_Delhi spoligotype and
the number and variety of types within the lineage sug-
gest that it has been present in the region for some time
and it is likely that lineages such as Beijing/W, T and
LAM7_TUR were more recently introduced. The high-
est proportion of CAS1_Delhi strains (66%) was
observed in patients from the poorly accessible Western
region but the majority of T1, LAM7_TUR and S strains
were found in the Eastern region which has access to
the Red Sea and international trading routes. Although
not highly significant, strains belonging to the CAS1_-
Delhi lineage were found more likely to have developed
drug resistance or MDR than those with other
spoligotype patterns. It has been speculated that Beijing
strains are growing in prevalence in some regions of the
world and that they are prone to drug resistance [31,32].
In this study two of the seven Beijing isolates identified
were found to be MDR. However, further studies shall
be required to determine the significance of this obser-
vation in the Sudanese population.
Spoligotyping provided a relatively simple and rapid
means of describing the population of tuberculosis
strains circulating in Sudan. However, we demonstrated
improved discrimination of strains sharing the CAS1_-
Dehli and Beijing spoligotypes when using MIRU-
VNTR. For future studies we recommend that secondary
typing with MIRU-VNTR be undertaken on all resistant
strains having identical spoligotypes. We also observed
that a batch of membranes supplied by the manufac-
turers consistently gave false positive results for one of
the spacers (position 33). Thus although simple to per-
form, spoligotyping requires careful monitoring to avoid
inappropriate interpretation of results.
Conclusion
Our findings suggest that the emergence of drug resis-
tant tuberculosis may be a serious problem in Sudan.
Expanded surveillance is required to determine the pre-
valence of drug resistant tuberculosis in Sudan. The
strong association of resistance with previous treatment
Table 4 Prevalence of MDR-TB within demographic subgroups
Variable N % MDR 95% CI RR 95% CI P-value
SEX Male 175 12.0 7.6,17.8 1
Female 60 8.3 2.8,18.4 0.69 0.27,1.76 0.435
AGE < = 30 86 7.0 2.6,14.6 1
31-44 84 17.9 10.4,27.7 2.56 1.04,6.28
> = 45 65 7.7 2.5,17.0 1.1 0.35,3.46 0.046
CASE New 164 4.9 2.1,9.4 1
Relapse 51 25.5 14.3,39.6 5.23 2.30,11.90
Failure/Interrupted 20 25 8.7,49.1 5.12 1.85,14.16 < 0.001
ORIGIN East 54 1.9 0.0,9.9 1
West 110 10.9 5.8,18.3 5.89 0.79,44.14
North 23 26.1 10.2,48.4 14.09 1.80,110.53
South 26 11.5 2.4,30.2 6.23 0.68,57.04
Central 22 18.2 5.2,40.3 9.82 1.16,82.99 0.026
SPOLIGOTYPE CAS1-DEL 114 13.2 7.6,20.8 1
Other 59 8.5 2.8,18.7 0.64 0.25,1.69
Unknown 62 9.7 3.6,19.9 0.74 0.30,1.80 0.597
MARITALSTATUS Married 118 9.3 4.7,16.1 1
Not married 117 12.8 7.4,20.3 1.38 0.66,2.87 0.393
TYPEOFHOUSE Brick 36 13.9 4.7,29.5 1
Mud 149 11.4 6.8,17.6 0.82 0.32,2.08
Shelter 47 8.5 2.4,20.4 0.61 0.18,2.12 0.737
PERSON/ROOM < 6 108 7.4 3.3,14.1 1
6+ 124 14.5 8.8,22.0 1.96 0.89,4.33 0.087
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observed suggests that improved monitoring of treat-
ment and direct observation of therapy should be imple-
mented to limit the emergence of drug resistant disease.
Our findings also suggest that the origin of the patient
is a risk factor for the development of resistance and
surveillance should be undertaken to assess geographic
differences in the effectiveness of TB treatment. The
dominant M. tuberculosis genotype lineage in the iso-
lates tested was CAS1_Delhi.
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